Form 4: Director Boosts Stake in Cue Biopharma

Cue Biopharma director Pasha Sarraf acquired 323,857 shares of common stock through multiple open market purchases.

Summary

• Pasha Sarraf, a director of Cue Biopharma, Inc. (CUE), reported multiple open market purchases of common stock.
• On December 30, 2025, Sarraf acquired a total of 323,857 shares across five separate transactions.
• The purchase prices for these transactions ranged from $0.3003 to $0.3174 per share.
• Following these transactions, Sarraf directly beneficially owns 323,857 shares of Cue Biopharma common stock.

Sentiment

Score: 8

Explanation: The director's substantial open market purchases of common stock signal strong confidence in the company's future prospects and current valuation, which is a significant positive indicator.

Positives

• A director's open market purchase signals strong confidence in the company's future prospects.
• The acquisition of 323,857 shares represents a significant increase in the director's direct beneficial ownership.
• The purchases were made at market prices, indicating a belief that the current stock valuation is attractive.

Future Outlook

NA

Industry Context

Insider buying, especially by a director, is often interpreted by the market as a positive indicator, suggesting that those closest to the company believe its shares are undervalued or that significant positive developments are anticipated. This can sometimes precede positive news or improved performance, signaling a bullish sentiment from within the company.

Comparison to Industry Standards

• Insider buying is a common occurrence across industries and is generally viewed more favorably than insider sales, which can sometimes signal a lack of confidence.
• The acquisition of 323,857 shares by Director Sarraf is a substantial increase in his direct beneficial ownership, indicating a strong personal conviction in the company's value proposition.

Stakeholder Impact

• Shareholders may view this as a positive signal, potentially increasing confidence in the company's stock.
• The increased insider ownership aligns the director's interests more closely with those of other shareholders.

Key Dates

Recommendation

The significant open market purchases by a director, Pasha Sarraf, totaling 323,857 shares, indicate strong insider confidence in Cue Biopharma's future performance and current valuation. Such insider buying often precedes positive company developments or improved financial results, making it a bullish signal for investors.

Keywords

Cue Biopharma, CUE, Insider Buying, Director Purchase, Stock Acquisition, Beneficial Ownership, Form 4